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The Efficacy of Metacognitive
Therapy: A Systematic Review and
Meta-Analysis
Nicoline Normann 1* and Nexhmedin Morina 2
1Department of Psychology, University of Copenhagen, Copenhagen, Denmark, 2Department of Clinical Psychology and
Psychotherapy, Institute of Psychology, University of Münster, Münster, Germany
Background: Metacognitive therapy (MCT) continues to gain increased ground as a
treatment for psychological complaints. During the last years, several clinical trials on the
efficacy of MCT have been published. The aim of the current study was to provide an
updated meta-analytic review of the effect of MCT for psychological complaints.
Methods: We conducted a systematic search of trials on MCT for young and adult
patients with psychological complaints published until January 2018, using PsycINFO,
PubMed, the Cochrane Library, and Google Scholar. Trials with a minimum of 10
participants in the MCT condition were included.
Results: A total of 25 studies that examined a variety of psychological complaints met
our inclusion criteria, of which 15were randomized controlled trials. We identified only one
trial that was conducted with children and adolescents. In trials with adult patients, large
uncontrolled effect size estimates from pre- to post-treatment and follow-up suggest
that MCT is effective at reducing symptoms of the targeted primary complaints, anxiety,
depression, and dysfunctional metacognitions. The comparison with waitlist control
conditions also resulted in a large effect (Hedges’ g = 2.06). The comparison of MCT to
cognitive and behavioral interventions at post-treatment and at follow-up showed pooled
effect sizes (Hedges’ g) of 0.69 and 0.37 at post-treatment (k = 8) and follow-up (k = 7),
respectively.
Conclusions: Our findings indicate that MCT is an effective treatment for a range of
psychological complaints. To date, strongest evidence exists for anxiety and depression.
Current results suggest that MCT may be superior to other psychotherapies, including
cognitive behavioral interventions. However, more trials with larger number of participants
are needed in order to draw firm conclusions.
Keywords: metacognitive therapy, meta-analysis, psychotherapy, anxiety, depression, psychopathology, mental
disorders
Metacognitive therapy (MCT; Wells, 2009) continues to gain ground as a treatment for
psychological complaints. MCT is theoretically grounded in the self-regulatory executive function
model (Wells and Matthews, 1994, 1996), which states that psychopathology arises as a result of a
perseverative thinking style called the cognitive attentional syndrome (CAS). The CAS consists of
dysfunctional coping strategies that a person employs as an attempt to manage distressful thoughts
and feelings. These include worry, rumination, threat monitoring, thought control strategies,
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avoidance, and reassurance seeking (Wells, 2009). The model
proposes that negative thoughts and feelings are temporary in
nature, however, when a person responds to these with CAS
activity, this may cause extended psychological distress and may
inadvertently exacerbate and prolong negative affect. The model
further suggests that the CAS arises from a person’s positive
and negative metacognitive beliefs, i.e., beliefs about cognition.
Positive metacognitions are beliefs about the need to engage in
CAS activities, e.g., “Worry helps me stay prepared,” whereas
negative metacognitions are beliefs about the uncontrollability
and dangerousness of thoughts and feelings, e.g., “I have no
control over my worry/rumination” and “Feeling like this means
I am losing my mind” (Wells, 2009).
In MCT, metacognitive beliefs and processes related to the
CAS are identified andmodified during treatment. The treatment
is manualized, as outlined by Wells (2009). However, flexible
application of the manuals is advocated to fit the specific
patient’s needs. Although MCT targets transdiagnostic processes,
the exact case formulation model as well as combination of
techniques vary depending on the disorder in question. The
first step in therapy is to conceptualize an idiosyncratic case
formulation together with the patient, and to socialize the patient
to the maintaining processes, including the impact of worry and
rumination and the ineffectiveness of current coping strategies.
Next, metacognitive beliefs are verbally challenged in Socratic
dialogues, and behavioral experiments are used to test and
generate change in the person’s metacognitive predictions or
beliefs about CAS strategies. Main emphasis is laid on challenging
the negative beliefs before moving on to challenging the positive
metacognitive beliefs. The patient is instructed to postpone
worry and rumination processes. The aim is for patient to
experience that worry and rumination are processes that can
be postponed by disengaging from further processing, that they
are harmless, and have no advantages. Specifically designed
therapeutic techniques, such as the attention training technique
or detached mindfulness (Wells, 2009), are used. The attention
training technique (Wells, 1990) is an auditory task that requires
the patient to engage in selective attention, divided attention,
and attention switching. It is designed to increase the patient’s
executive control and regain attentional flexibility. In detached
mindfulness the patient is instructed to become aware of internal
trigger thoughts and detach from them by taking a step back
and disengaging any further coping or perseverative processing
in reaction to them. The patient practices these new ways of
reacting to trigger thoughts in therapy as well as between sessions,
and their implementation is proposed to strengthen the patient’s
ability to disengage from worry and rumination processes. The
techniques furthermore challenge the patient’s belief that worry
and rumination are uncontrollable. Toward the end of therapy
focus is on reversing any residual CAS activity. Altogether, MCT
aims at increasing the person’s experience of attentional control,
reducing self-focused attention, and fostering the development of
adaptive beliefs and coping strategies.
Several clinical trials have examined the efficacy of MCT.
Normann et al. (2014) meta-analytically summarized relevant
trials on MCT that were published until early 2014. The authors
incorporated 16 trials with patients with anxiety and depression
and concluded that MCT is very effective in these populations.
It must be noted, however, that only nine of the trials in
this meta-analysis were controlled trials and most trials were
based on rather small samples. Very recently, Rochat et al.
(2018) assessed the efficacy of single-case studies on MCT in
a meta-analytic review and also reported that these studies
support treatment efficacy of MCT for anxiety, depression, and
other psychopathological symptoms. Since the meta-analysis
by Normann et al. (2014), several clinical trials on the effect
of MCT have been published. Furthermore, the meta-analysis
by Normann et al. (2014) focused on depression and anxiety
disorders only. To address these limitations, the current study
aimed at providing an updated review and meta-analysis on
the effect of MCT. The main objective was to investigate
whether MCT improves symptoms of psychological complaints
on primary and secondary outcome variables in comparison
to control conditions. For this purpose, we focused on both
uncontrolled as well as controlled trials. With regard to the
secondary outcomes, we aimed at assessing whether treatment
has an impact on comorbid anxiety or depression as well as
metacognitions.
METHODS
The aims and methods of this meta-analysis have been
registered with the International Prospective Register for
Systematic Reviews, with ID number CRD42018084507
(available from https://www.crd.york.ac.uk/PROSPERO). The
meta-analysis was conducted using the guidelines and checklist
outlined by the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) Group (Moher et al.,
2009). Accordingly, our main research question describing
the Population, Intervention, Comparison, Outcome, and
Study design (PICOS) was: In individuals with psychological
complaints (P), does metacognitive therapy (I), compared to
control conditions (C), improve symptoms of psychopathology
(O) in randomized controlled trials (S)? However, due to the
limited number of controlled trials meeting our criteria, we
decided to also include uncontrolled trials and thus first examine
the efficacy of treatment with respect to within-group effect sizes
(i.e., change from pre- to post-treatment or follow-up). We first
examined the efficacy of treatment from pre- to post-assessment
for the primary outcome of all included studies. However, since
uncontrolled effect sizes do not account for the impact of time on
symptoms, we view controlled effect sizes as more reliable when
it comes to assessing treatment efficacy. We also calculated effect
sizes for secondary outcome measures of anxiety, depression
and metacognitions to the extent these were available. With
respect to between-group analyses, we calculated effect sizes for
the primary outcome on studies comparing MCT with waitlist
control and active treatment control conditions, respectively.
Eligibility Criteria
The criteria for inclusion of a trial in the meta-analysis were:
The study had to (1) evaluate MCT as developed by Adrian
Wells, and (2) have a sample size of at least 10 patients
with psychological complaints in the MCT condition. In order
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to include as many trials as possible, we did not place any
a priori restrictions on study design, comparison conditions,
age of participants, publication type, or statistical presentation
of results. We excluded studies that examined specific MCT
techniques in isolation (e.g., attention training) as opposed to the
treatment as a whole, and studies that combinedMCT techniques
with other types of therapy, e.g., cognitive therapy. Studies had
to be written in English, Danish, Norwegian, Swedish, Dutch, or
German in order to be included, as these were the languages at
least one of the authors is proficient in.
Literature Search
As this study is an update of a previous meta-analysis (Normann
et al., 2014), trials that were included in the previous meta-
analysis were also included in this meta-analysis if they fulfilled
our current inclusion criteria. We identified additional studies by
searching the databases PsycINFO, PubMed, and the Cochrane
Library for the period between January 2014 and January
2018, using the search string “(metacognitive or meta-cognitive)
AND (therapy OR trial OR treatment OR psychotherap* OR
intervention).” We also conducted a backward search of the
reference lists from articles that met the inclusion criteria.
Further, trial registries (www.clinicaltrials.gov; www.isrctn.com)
were searched for potential completed trials on MCT. Google
Scholar was included as an additional information source. In
Google Scholar the search string was limited to articles that
used the term “metacognitive therapy” in their title, as the full
search string yielded more than 1,000 hits, which is more than
the database was able to display. The last search was conducted
January 11th, 2018.
Study Selection and Data Extraction
After removing duplicates, the titles and abstracts of all search
hits were screened, and those that did not fulfill our inclusion
criteria were excluded. The full text versions of the remaining
records were retrieved and assessed for eligibility for inclusion
in the meta-analysis. The final list of studies was jointly discussed
by both authors.
For each included publication, a list of study characteristics
was extracted: type of psychological complaint treated,
comparison conditions, sample size, attrition rates at the
end of therapy, gender distribution, mean age, comorbidity rates,
number of therapy sessions, intervention format (individual or
group), follow-up period(s) from the end of therapy, statistical
analyses (completer or intent-to-treat), and treatment fidelity
checks. We also extracted information for the effect size
calculation, namely means and standard deviations for the
primary and secondary outcome measures at pretreatment,
post-treatment and the longest reported follow-up period
available. Data from intent-to-treat samples was used to the
extent possible. The primary outcome measure was chosen
based on which measure had the most specific relevance for the
psychological complaint in question. If a study did not provide
sufficient data for performing the meta-analysis, or if central
study characteristics were lacking, the information was requested
from the authors of the study in question via e-mail. Study
selection and extraction of study characteristics was performed
by the first author, in consultation with the second author.
Risk of Bias Assessment
We assessed the quality of reporting of each included study
with the Risk of Bias tool developed by the Cochrane
Collaboration (Higgins et al., 2011). The risk of bias of
the individual studies was examined across six domains:
random sequence generation, allocation concealment, blinding
of outcome assessment, incomplete outcome data, selective
reporting, and other sources of bias. Each domain was assigned
a judgement of low, unclear, or high risk of bias. An “unclear”
judgement was given if the reporting of what happened in the
study was not described in suffice detail to allow judgement of
either low or high risk of bias. We did not assess the blinding
of participants and personnel (performance bias), as it is not
feasible to blind therapists and clients to a psychotherapeutic
intervention. In order to ensure consistency in the judgements
across all studies, we chose to reassess the risk of bias for the
studies from the previous meta-analysis, as those judgements
were based on three raters. Four studies were consensus-
coded by both authors, and interrater reliability was established
for the remaining studies, which were all double-coded. The
intraclass correlation coefficient using a two-way random effects
model (absolute agreement; single measurement) was 0.84, 95%
CI [0.78–0.89], indicating very good reliability. Subsequently,
discrepancies in the codes were handled through discussion, until
consensus was reached.
Statistical Analyses Plan
The meta-analysis was carried out using the software program
Comprehensive Meta-Analysis (version 3.3; Borenstein et al.,
2009). Due to the heterogeneity of the included studies, we
expected there to be natural variations in the distribution of
the true effect sizes, and therefore a random effects model
was used (Borenstein et al., 2009). Hedges’ g was chosen as
the effect size metric throughout the meta-analysis. Similarly
to Cohen’s d, it is based on the standardized mean difference,
but it applies a correction factor to obtain an unbiased
estimate in small samples (Borenstein et al., 2009). Values of
0.2, 0.5, and 0.8 can be conservatively interpreted as small,
medium, and large magnitudes of effect, respectively (Cohen,
1988). The correlation between the measures at pre- and
post-treatment and pretreatment and follow-up was needed
for the effect size calculation, and this was not provided in
the studies. As recommended by Morris and DeShon (2002),
we retrieved these correlations from authors in a subset of
the studies, and conservatively estimated the correlation to
r = 0.50, which corresponded to the upper limits of the
confidence intervals of the aggregate correlations in the subset
of studies.
As mentioned above, we first computed within-group
effect sizes (i.e., change from pre- to post-treatment or
follow-up) for the primary outcome of all included studies
at post-treatment and follow-up. We also calculated effect
sizes for secondary outcome measures of anxiety, depression
and metacognitions, to the extent these were available. With
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regard to between-group analyses, we calculated effect sizes
for the primary outcome on studies comparing MCT with
waitlist control and active treatment control conditions,
respectively.
In order to measure variability in the study outcomes, we used
the I2 statistic, which describes the percentage variation across
studies that is due to heterogeneity rather than chance. It has been
suggested that I2 values of 25, 50, and 75% may be interpreted
as referring to low, moderate, and high levels of heterogeneity
(Higgins et al., 2003). We further performed subgroup analyses
for subgroups of at least four trials, as has been recommended
(Fu et al., 2011). Due to the low number of trials included in
these analyses, the p-value for statistical significance was set
to 0.1.
We also assessed potential publication bias using visual
inspection of funnel plots of the primary outcome measures.
In accordance with recommendations from Sterne et al.
(2011), publication bias was assessed if there was a minimum
of 10 studies available. Particularly, we were interested in
examining whether there was an asymmetry in the plot
with smaller studies having larger effect sizes, which is
indicative of publication bias (Sterne et al., 2011). The
trim-and-fill procedure by Duval and Tweedie (2000) was
used to calculate the likely number of missing studies
and estimate an effect size that corrects for publication
bias.
RESULTS
Search Results and Study Selection
Figure 1 displays a PRISMA (Moher et al., 2009) flow diagram
of the study selection process. A total of 1536 records were
identified, and 25 trials were eligible for inclusion in the final
meta-analysis. Eleven of the eligible studies were from the 2014
search (of which nine were included in the analyses), whereas
the additional 14 studies were identified through the updated
search. Two of these (Wells et al., 2015; Nordahl et al., 2018)
were peer-reviewed publications of trials that were included in
the first meta-analysis, which at that time only were available as
dissertations. With the exception of one study (Esbjørn et al.,
2018), all other studies that fulfilled our inclusion criteria were
conducted with adult populations. Our results therefore focus on
the efficacy of MCT for adults only.
Study Characteristics
Table 1 provides an overview of the studies included in the meta-
analysis, along with their study characteristics. We included 25
trials based on 26 records. Of these, 10 studies compared MCT
with active control conditions, 9 compared MCT with waitlist
control conditions, and 10 were uncontrolled trials. Eight of
the active control conditions were cognitive and/or behavioral
interventions. These included generic and disorder-specific
cognitive behavioral therapy (k = 5), behavioral activation
FIGURE 1 | Flow diagram of study selection process.
Frontiers in Psychology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 2211
Normann and Morina Efficacy of Metacognitive Therapy
(k = 1), applied relaxation (k = 1), and prolonged exposure
(k = 1). Other interventions included mindfulness-based stress
reduction (k= 1) and Masters-Johnson sex therapy (k= 1).
The trials were conducted in the United Kingdom (k = 10),
Norway (k = 6), Iran (k = 4), the Netherlands (k = 3), Australia
(k = 1) and New Zealand (k = 1). One study was a PhD
dissertation (Wenn, 2017), one was an unpublished manuscript
(Shareh and Dolatshahi, 2012), and the remaining 24 records
were articles published in peer-reviewed journals.
Patient Characteristics
A large proportion of the identified studies treated patients
suffering from anxiety and depression (see Table 1). There were
eight trials on depressive disorders. Of these, seven were on
major depressive disorder, whereas one study also included
a small proportion of patients with bipolar II and bipolar
not-otherwise-specified (Jordan et al., 2014). Five trials were
conducted on generalized anxiety disorder, three were conducted
on post-traumatic stress disorder, and three were conducted
on transdiagnostic samples with anxiety and/or depression.
The remaining six trials were on cancer distress, schizophrenia
spectrum disorders, body dysmorphic disorder, hyposexual
desire disorder, obsessive-compulsive disorder, and grief.
The majority of studies included participants that fulfilled
criteria for a psychological disorder according to either DSM-IV-
TR (American Psychiatric Association, 2000) or ICD-10 (World
Health Organization, 1992) criteria. Two studies (Fisher et al.,
2015; Capobianco et al., 2018) did not use structured psychiatric
interviews, but rather included patients with elevated levels of
anxiety and/or depression based on a cut-off score from a self-
report. One study (Wenn, 2017) assessed diagnostic criteria,
but also included participants who did not meet the criteria in
question. With few exceptions, the reported comorbidity rates
were high. Four studies did not report comorbidity rates, and one
study (Ramezani et al., 2017) excluded patients with comorbid
disorders. For the 17 studies that reported comorbidity rates
in percentages, the mean for the MCT conditions was 65%
(standard deviation 24, range 0–100%). These were primarily
Axis I disorders consisting of anxiety and depressive disorders.
Few studies also reported relatively low rates of substance abuse
and eating disorders. Further, inclusion of patients with certain
Axis II disorders was reported in seven studies, with reported
rates ranging between 8.3 and 50%. Seven studies specified that
they worked with refractory cases (ranging from 25 to 100% of
participants) that had not previously responded to other forms
of psychotherapy. One study was conducted on an inpatient
group (Johnson et al., 2017), whereas the remaining studies were
conducted in outpatient settings. All studies used adult samples,
with the exception of one study that also included adolescents
from age 16 and up (Rabiei et al., 2012).
Altogether, 780 patients were included in the meta-analysis.
Of these, 468 were offered MCT and meta-analyzed at post-
test. In the post-test comparisons with waitlist controls, 208
patients were in the MCT condition and 125 were in the control
condition. Data from control patients that received treatment
after their waiting period was included and thus meta-analyzed
twice in separate groups. In the post-test comparison with active
treatment controls, 234 patients were in the MCT condition
and 232 were in the control condition. The mean number of
participants included in each trial was 31.2 (standard deviation
27.3, range 10–126).
Metacognitive Therapy
Individual therapy was applied in 18 of the trials, whereas a
group format was applied in seven studies. The vast majority of
studies (n= 18) followed a published disorder-specific treatment
manual for the primary disorder, whereas four studies followed
the generic model of intervention as presented by Wells (2009).
Three studies (Rabiei et al., 2012; Morrison et al., 2014; Ramezani
et al., 2017) investigated a psychological disorder for which
no formal manual had yet been developed. In these cases, the
authors had adapted a treatment manual for another disorder
to the disorder in question. Number of mean therapy sessions
ranged from 6 to 14, with an overall mean of 9.5 (standard
deviation 2.3) across all 25 studies. Group sessions tended to
last between 90 and 120min, whereas individual sessions usually
were between 45 and 60min. Typically, MCT was conducted
weekly. However, some trials chose to intensify treatment in the
beginning of therapy, and others chose to prolong treatment as
to allow for incorporation of techniques into everyday life. For
example, the study on schizophrenia delivered 12 sessions over
approximately 9 months (Morrison et al., 2014). With regard to
treatment fidelity, the majority (n = 19) of studies reported that
continued supervision was provided from experts in order to
ensure adherence to the treatment protocols. However, only six
studies had assessed treatment fidelity in a formal manner, i.e.,
with checklists and video or audio recordings, and conclude that
therapists adequately adhered to the protocols.
Outcome Measures
The primary outcome measure of each study is presented in
Table 1. With regard to the secondary outcome measures, in the
majority of cases the Beck Anxiety Inventory (Beck et al., 1988)
and Beck Depression Inventory(-II) (Beck et al., 1961, 1996)
were used as measures of anxiety and depression symptoms,
respectively. With respect to measures of metacognition,
the Metacognitions Questionnaire(-30) (Cartwright-Hatton and
Wells, 1997; Wells and Cartwright-Hatton, 2004), the Positive
Beliefs about Rumination Scale (Papageorgiou and Wells, 2001)
and the Negative Beliefs about Rumination Scale (Papageorgiou
et al., 2003) were mostly used. Thirteen of the publications
reported on the efficacy of treatment on positive and negative
metacognitions separately, whereas five publications reported
on the efficacy of MCT on metacognitions in general, without
distinguishing between positive and negativemetacognitions.We
conducted the analyses accordingly. The measures included in
each of the secondary analyses are listed in Table 3.
Follow-Up
Out of the 25 studies, 22 had follow-up data that was included in
our analyses. The mean length of the included follow-up periods
was 8.2 months from post-treatment (standard deviation 5.9,
range 3–24 months). As displayed in Figure 1, we excluded one
publication (van der Heiden and Melchior, 2014), which was a
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TABLE 1 | Study characteristics.
Psychological
complaint
Study and
treatment type
Primary
outcome
Treatment
format
n
analyzed
%
attrition
Flw-up
months
% female Mean age Comorbidity Therapy
sessions
Statistical
analysis
DEPRESSIVE DISORDERS
MDD Dammen et al., 2015, 2016
MCT BDI Group 11 0 24 100 42.3 91% 11.5 (ITT)a
MDD Hagen et al., 2017
MCT BDI Individual 39 5.4 6 59 33.7 67%b 10 ITT
WL 19 10.5 53 35.4
MDD Hjemdal et al., 2017
MCT BDI Individual 10 0 6 80 28.4 100% 10 (ITT)
Depressive
disorders
Jordan et al., 2014
MCT QUIDS16-
C
Individual 23 21.7 6 48 37.2 Minimum
74%c
11.5d ITT
CBT Individual 25 24 48 35.0 Minimum
60%c
11.5d
MDD Papageorgiou and Wells, 2015
MCT BDI Group 10 0 6 80 41.7 90% 14 (ITT)
MDD Shareh and Dolatshahi, 2012
MCT BDI Group 10 16.7 – 80 NI NI 8 Compl
WL 10 16.7 60 NI NI
MDD Wells et al., 2012
MCT BDI Individual 12 16.7 12 92 34.5 75% 6.5 ITT
MDD Zemestani et al., 2016
MCT BDI Group 15 0 3 61 b 24.2b 19 diagnoses
on n 45b
8 (ITT)
BA Group 15 0 8
WL 15 0
GENERALIZED ANXIETY DISORDER
Nordahl et al., 2018
MCT PSWQ Individual 32 0 24 75 37.0 44 diagnoses 12 ITT
CBT Individual 28 0 68 38.6 41 diagnoses 12
WL 21 0 76 37.9 35 diagnoses
van der Heiden et al., 2012
MCT PSWQ Individual 61 18.0 6 70 33.9 59% 12.3 ITT
IUT Individual 60 23.3 69 34.4 60% 12.9
WL 20 5.0 90 39.6 75%
van der Heiden et al., 2013
MCT PSWQ Group 33 27.3 (6) 64 31.3 73% 12.9 ITT
Wells and King, 2006
MCT STAI-T Individual 8 (10)e 0 12 60 (25-75) 50% 7.4 (ITT)
Wells et al., 2010
MCT PSWQ Individual 10 0 12 60b 49.1b 80%b 12 (ITT)
AR Individual 10 0 12
POST-TRAUMATIC STRESS DISORDER
Wells et al., 2008
MCT IES Individual 11 15.4 6 55 38.9 55% 8.5 Compl
Wells and Colbear, 2012
MCT PDS Individual 10 10 6 60 33.4 8 diagnoses 6.4 ITT
WL 10 0 50 41.3 6 diagnoses
(Continued)
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TABLE 1 | Continued
Psychological
complaint
Study and
treatment type
Primary
outcome
Treatment
format
n
analyzed
%
attrition
Flw-up
months
% female Mean age Comorbidity Therapy
sessions
Statistical
analysis
Wells et al., 2015
MCT PDS Individual 10 9.1 3 36 40.6 46% 8 Compl
PE Individual 10 9.1 36 40.5 55% 8
WL 10 0 40 42.7 70%
TRANSDIAGNOSTIC SAMPLE
Anxiety and
depression
Capobianco et al., 2018
MCT HADS Group 17 17.6 6 72 30.4 NI 8 ITT
MBSR Group 18 27.8 70 26.7 NI 8
Anxiety Johnson et al., 2017
MCT BAI Individual 36 5.6 12 61b 42.0b 91%b 9.4 ITTf
CBT (disorder
specific)
Individual 38 13.2 9.4
Mixed disorders Nordahl, 2009
MCT BAI Individual 15 0 - 60 37.2 31 total
diagnoses
7.5 Compl
CBT Individual 13 13.3 62 34.9 26 total
diagnoses
10.2
OTHER PSYCHOLOGICAL COMPLAINTS
Cancer distress Fisher et al., 2015
MCT HADS Individual 12 16.7 6 33 20.7 NI 7.8 ITT
Schizophrenia Morrison et al., 2014
MCT PANSS Individual 10 20 3 20 34.3 NI 10.6 ITT
Body
dysmorphic
disorder
Rabiei et al., 2012
MCT BDD-
YBOCS
Individual 10 0 6 90b 23.7 40% 8 (ITT)
WL 10 0 26.6 50%
Hyposexual.
desire disorder
Ramezani et al., 2017
MCT FSFI Individual 15 NI 6 80 32.1 0% 10 Compl
MJST Individual 15 NI 73 33.3 0% 10
Obsessive
compulsive
disorder
van der Heiden et al., 2016
MCT Y-BOCS Individual 25 24 3 68 32.3 52% 13.7 ITT
Grief Wenn, 2017
MCT PG-13 Group 21 21.1 6 95b 62 Minimum
64%c
6 ITT
WL 10 10 62 Minimum
50%c
Percent attrition is at post-treatment. Follow-up months indicates the longest follow-up period from post-treatment, and parenthesis indicates that the follow-up was not used in the
analyses. Means are given for number of therapy sessions, and if means are not available, the maximum number of sessions allowed is stated. N analyzed refers to number of participants
that data was available for. aFollow-up analyses did not use ITT. bRefers to the total sample, as data was not available for each group. cComorbid anxiety disorders. dMedian number
of sessions. e8 analyzed for primary outcome, 10 for secondary outcomes. fMCQ data was based on completers. AR, applied relaxation; BA, behavioral activation; BAI, Beck Anxiety
Inventory; BDD-YBOCS, Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder; BDI, Beck Depression Inventory; CBT, cognitive behavior therapy; Compl,
completer analysis; FSFI, Female Sexual Function Index; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Events Scale; ITT, intention-to-treat analysis; (ITT), no attrition,
thus equivalent to intention-to-treat analysis; IUT, intolerance-of-uncertainty therapy; MBSR, mindfulness based stress reduction; MDD, major depressive disorder; MJST , Masters-
Johnson Sex Therapy; NI, No information; PANSS, Positive and Negative Syndromes Scale; PDS, Post-traumatic Stress Diagnostic Scale; PE, prolonged exposure; PG13, Prolonged
Grief Disorder Scale; PSW Q, Penn State Worry Questionnaire; QUIDS16-C, Quick Inventory of Depressive Symptomatology-Clinician rating; STAI-T, State-Trait Anxiety Inventory—Trait
scale; WL, waitlist; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
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30-month follow-up of an included trial (van der Heiden et al.,
2012), as the publication reported on 34 out of the original 126
participants. We further chose not to include the follow-up data
in another study (van der Heiden et al., 2013), as the authors
had not included the data in their primary analysis due to a large
dropout rate.
Risk of Bias
Table 2 presents the risk of bias of each included study. Overall,
the most prevalent rating given was low risk of bias. However,
unclear risks of bias were present with regard to allocation
concealment, as only 5 out of the 15 controlled trials had
described in adequate detail how the randomization schedule
was concealed, so that participants and assessors could not
foresee which treatment they were allocated to. Separating
the randomization from the recruitment process is essential
for ensuring that researchers or assessors do not influence
assignment of potential participants to treatment arms. Of the 25
studies, 18 had an unclear risk of selective reporting, as they did
not report whether they had published a study protocol for the
study. We found high risks of attrition bias in five studies, where
intent-to-treat analyses were not applied. Furthermore, we found
high risks of detection bias in two studies, as they had not blinded
the outcome assessor for the primary outcome measure at post-
treatment. Altogether, the risk of bias was rated as low in 73% of
cases, unclear in 23% of the cases, and high in 4% of the cases.
Furthermore, the trials did not differ substantially on risk of bias
and thus this variable could not be included in subanalyses.
Treatment Effects
Within-Group Effect Sizes
Figure 2 displays a forest plot of the effect sizes from pre-
to post-treatment on the primary outcome measures across
all 25 included studies. The pooled pre- to post-treatment
effect size was large, g = 1.72, 95% CI [1.44–2.00], p <
0.001, and this effect was maintained over time, as evidenced
by the large pretreatment to follow-up effect size, g = 1.57,
95% CI [1.26–1.87], p < 0.001, k = 22. Subanalyses revealed
that MCT also resulted in large and significant reductions of
secondary outcome measures that included anxiety, depression,
and dysfunctional metacognitions (see Table 3). The pooled
effect sizes on the primary outcomemeasures and for measures of
anxiety, depression, and metacognitions are displayed in Table 3.
Between-Group Effect Sizes
Figures 3A,B display the pre- to post-treatment effect sizes and
forest plots for MCT compared with waitlist and active control
conditions for the primary outcome measures. A large pre- to
post-treatment effect size was found for the studies comparing
MCT to waitlist controls on primary outcomemeasures, g = 2.06,
95% CI [1.52–2.60], k = 9. Only two studies assessed the efficacy
of MCT as compared to the waitlist at follow-up, therefore no
meta-analytic synthesis was conducted.
Comparison of MCT with active control conditions revealed
a medium to large effect size in favor of MCT, g = 0.68, 95%
CI [0.41–0.95], k = 10. This comparison at follow-up revealed
a small to medium effect size favoring MCT, g = 0.39, 95% CI
[0.15–0.63], k = 9. Given that eight out of ten active control
conditions were cognitive and behavioral interventions (see
Table 1), we also focused on the comparison of MCT to these
interventions. Compared to behavioral activation and cognitive
behavior therapy (CBT), a medium to large effect size was found
favoring MCT, g = 0.69, 95% CI [0.36–1.03], k= 8. Compared to
behavioral activation and CBT at follow-up, a small to medium
effect size was found favoringMCT, g = 0.37, 95% CI [0.07–0.66],
k= 7.
Heterogeneity
For the pre- to post-treatment within-group effect size on
primary outcome measures I2 was 69.74%, Q = 79.84, p = <
0.001, indicating a high degree of variability in the study
outcomes. Similarly, high heterogeneity was observed at follow-
up (I2 = 74.63, Q = 82.79, p = < 0.001). For the comparison
of MCT with waitlist and cognitive behavioral interventions,
heterogeneity values were also large, I2 = 71.84%, Q = 28.41,
p = <0.001 and I2 = 59.09%, Q = 17.11, p = < 0.001,
respectively. We explored the possible sources of heterogeneity
by undertaking subgroup analyses, given that at least four trials
could be included in the category of interest.
Subgroup Analyses
The subgroup analyses were undertaken using within-group
effect sizes, as no relevant subanalyses could be conducted on
between group effect sizes. This was the result of a low number
of trials in the categories of interest. For example, none of
the disorders were investigated in four or more randomized
controlled trials that compared the efficacy of MCT to waitlist or
an active control condition.
One of the trials produced an effect size of g = 6.14 from
pre- to post-treatment (Dammen et al., 2015), which may be
considered as an outlier from the pooled mean effect size of
g = 1.72. When this study was excluded, the pre- to post-
treatment and pretreatment to follow-up effect sizes did not
change substantially (g = 1.66, 95% CI [1.40–1.91] and g = 1.51,
95% CI [1.22–1.80], respectively).
With respect to the efficacy of MCT for specific psychological
complaints, only two disorders were investigated in four or
more trials and thus enabled subanalyses. For trials with patients
with depression, a large within-group effect size was obtained,
g = 2.68, 95% CI [1.85–3.51], k = 8. A large effect size was
also produced when only the trials with patients with GAD were
analyzed at post-treatment, g = 1.61, 95% CI [1.23–1.98], k= 5.
Because 13 of the trials were co-authored by the originator
of MCT (Adrian Wells), the possibility of allegiance bias was
examined by comparing the results of these studies with the
remaining studies. Both groups of publications revealed large
effect sizes, with g =1.98, 95% CI [1.52–2.44] for studies byWells
and colleagues and g = 1.49, 95% CI [1.17–1.81] for studies
by independent authors. The results indicated that the studies
conducted by Wells and colleagues produced significantly higher
effect sizes (p = 0.09). However, when the above mentioned
potential outlier (Dammen et al., 2015) was removed, the effect
size of the trials conducted by Wells and colleagues was reduced
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TABLE 2 | Risk of bias.
Selection bias Detection bias Attrition bias Reporting bias Other bias
Study Randomsequence
generation
Allocation
concealment
Blinding of outcome
assessment
Incomplete
outcome data
Selective
reporting
Other sources
of bias
Capobianco et al.,
2018
Low Low Low Low Low Low
Dammen et al., 2015,
2016
– – Low High Unclear Low
Johnson et al., 2017 Low Unclear Low Low Low Low
Jordan et al., 2014 Low Low High Low Low Low
Fisher et al., 2015 – – Low Low Unclear Low
Hagen et al., 2017 Low Unclear Low Low Low Low
Hjemdal et al., 2017 – – Low Low Unclear Low
Morrison et al., 2014 – – Low Low Unclear Low
Nordahl, 2009 Low Low Low High Unclear Low
Nordahl et al., 2018 Low Unclear Low Low Low Low
Papageorgiou and
Wells, 2015
– – Low Low Unclear Low
Rabiei et al., 2012 Unclear Unclear High Low Unclear Low
Ramezani et al., 2017 Low Unclear Low Unclear Unclear Low
Shareh and Dolatshahi,
2012
Unclear Unclear Low High Unclear Low
van der Heiden et al.,
2012
Low Unclear Low Low Unclear Low
van der Heiden et al.,
2013
– – Low Low Unclear Low
van der Heiden et al.,
2016
– – Low Low Unclear Low
Wells and King, 2006 – – Low High Unclear Low
Wells et al., 2008 – – Low High Unclear Low
Wells et al., 2010 Low Low Low Low Unclear Low
Wells et al., 2012 – – Low Low Unclear Low
Wells and Colbear,
2012
Low Unclear Low Low Unclear Low
Wells et al., 2015 Low Low Low Low Low Low
Wenn, 2017 Low Unclear Low Low Low Low
Zemestani et al., 2016 Low Unclear Low Low Unclear Low
to g = 1.84, 95% CI [1.43–2.24], k = 12, and the difference
between the groups was no longer significant (p= 0.19).
Studies that had applied intent-to-treat analyses, including
those without dropouts displayed a significantly lower effect
(g = 1.60, 95% CI [1.32–1.89], k = 20) as opposed to those
that based their results on completer analyses (g = 2.50, 95% CI
[1.52-3.49], k= 5), p= 0.08.
With regard to treatment format, we found that studies that
had applied an individual treatment format had a significantly
lower effect size (g = 1.57, 95% CI [1.30-1.84], k = 18) than
the trials with a group format (g = 2.45, 95% CI [1.59–
3.30], k = 7), p = 0.06. However, when the above mentioned
potential outlier (Dammen et al., 2015) was removed, the
effect size of the trials applying a group format was reduced
to g = 2.09, 95% CI [1.34–2.84], k = 6, and the difference
between the groups was no longer significant (p = 0.20). Finally,
meta-regressions indicated that pre- to post-treatment changes in
positive or negative metacognitions did not significantly explain
heterogeneity (Q= 0.91, p= 0.34 for positivemetacognitions and
Q= 0.59, p= 0.44 for negative metacognitions).
Publication Bias
Inspection of the funnel plot depicting the within-group pre-
to post-treatment effect sizes for the primary outcome measures
revealed an asymmetry indicative of potential publication bias,
as the direction of the effect of the smaller trials was toward the
right side of the plot, i.e., toward higher effect sizes. Duval and
Tweedie’s (2000) trim-and-fill procedure identified six studies to
be missing, and the produced imputed point estimate resulting
from the analysis was g = 1.49, 95% CI [1.19–1.79]. Accordingly,
the effect size was still large. A pattern of asymmetry was
also observed when trials comparing MCT to active control
conditions at pre- to post-treatment were examined. Here, Duval
and Tweedie’s (2000) trim-and-fill procedure identified three
studies to be missing, and the produced imputed point estimate
resulting from the analysis was g = 0.53, 95% CI [0.24; 0.82].
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FIGURE 2 | Forest plot of within-group effect size estimates for the efficacy of MCT on primary outcome measures from pre- to post-treatment. BDD, body
dysmorphic disorder; GAD, generalized anxiety disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress disorder.
TABLE 3 | Pre- to post-treatment and pretreatment to follow-up effect sizes.
Domain Post-treatment Follow-up
Hedges’ g 95% CI k Z Hedges’ g 95% CI k Z
Primary outcome 1.72 1.44–2.00 25 12.19 1.57 1.26–1.87 22 10.13
Anxiety as secondary outcome 1.48 1.18–1.78 17 9.64 1.32 1.06–1.58 15 9.95
Depression as secondary outcome 1.12 0.86–1.39 12 8.19 0.97 0.71–1.23 11 7.23
Positive MC 0.86 0.58–1.15 13 5.95 1.02 0.76–1.28 11 7.69
Negative MC 1.31 1.01–1.62 13 8.60 1.28 1.01–1.55 11 9.32
General MC 1.79 0.66–1.70 5 9.57 n.a.
k, number of studies included in the analysis; n.a., not applicable, as number of trials too small to conduct analysis; MC, metacognitions. Effect sizes were based on the following
questionnaires: For anxiety: Beck Anxiety Inventory; Depression Anxiety Stress Scales-Anxiety; Hospital Anxiety and Depression Scale-Anxiety; State-Trait Anxiety Inventory-Trait. For
depression: Beck Depression Inventory; Beck Depression Inventory-II; Depression Anxiety Stress Scales-Depression; Hospital Anxiety and Depression Scale-Depression. For positive
metacognitions: Cognitive Attentional Syndrome-1 (positive belief items); Metacognitive Questionnaire (MCQ) or MCQ-30 (positive beliefs subscale); Positive Beliefs about Rumination
Scale. For negative metacognitions: Cognitive Attentional Syndrome-1 (negative belief items); Metacognitive Questionnaire (MCQ) or MCQ-30 (negative beliefs about uncontrollability
and danger subscale); Negative Beliefs about Rumination Scale. For general metacognitions: Anxious Thoughts Inventory-Meta Worry; Thought Control Questionnaire-Worry; Thought
Fusion Inventory.
Given that fewer than 10 trials compared MCT to a waitlist,
publication bias could not be assessed in this regard.
DISCUSSION
In this meta-analysis, we set out to investigate whether MCT
improves symptoms of psychological complaints on primary
and secondary outcome variables in comparison to control
conditions.Wewere able to assess the efficacy of 25 trials onMCT
for a variety of psychological complaints, altogether examining
780 adult patients. Due to the relatively low number of studies,
we computed both within- and between-group effect sizes. Our
results indicate that MCT is effective in alleviating psychological
symptomatology as well as maladaptive metacognitions. The
results further suggest that MCT is superior to waitlist and active
treatment control conditions.
We were able to include 16 trials that were not part of the first
meta-analysis on the efficacy of MCT (Normann et al., 2014).
In contrast to the first meta-analysis, we included studies on a
variety of other psychological complaints, rather than on anxiety
and depression only. Despite the stricter inclusion criteria for
trials (i.e., a minimum of 10 participants instead of five), the effect
sizes found in this meta-analytic update were largely comparable
to those found previously (Normann et al., 2014). The within-
group analyses yielded overall large effects from pre- to post-
treatment across the included trials (g = 1.72), and these were
maintained at follow-up (g = 1.57). Similarly, in nine trials MCT
was compared to waitlist control conditions, and large effects
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FIGURE 3 | (A) Pre- to post-treatment effect sizes and forest plots for MCT compared to waitlist control conditions. (B) Pre- to post-treatment effect sizes and forest
plots for MCT compared to active control conditions.
were found in favor of MCT (g = 2.06). Compared to the last
meta-analysis, these results have the advantage of being based on
a larger number of studies in each of these groups.
In 10 trials, the efficacy of MCT was compared to a range
of other psychotherapeutic interventions. One strength of the
included control conditions is that they were evidence-based
treatments for the respective disorders. We found that MCT
resulted in significantly higher symptom reduction on the
primary outcome measures as compared to other therapies,
with a medium to large effect size at post-treatment and a
small to medium effect size at follow-up. Eight out of 10
of the comparison conditions were forms of cognitive and/or
behavioral interventions. When comparing the CBT conditions
with MCT, MCT also outperformed CBT at post-treatment and
follow-up with a medium to large (g = 0.69) and a small to
medium (g = 0.37) effect size, respectively. This is a slightly
lower difference in effect than that previously reported, which
was based on five trials and resulted in a large pre- to post-
treatment effect size in favor of MCT (g = 0.97) (Normann
et al., 2014). Although our results indicate that the effect of MCT
was significantly higher than in the active control conditions,
this is a finding that needs to be interpreted with caution.
The number of studies included in these analyses was low
and there were variations in the findings across the studies.
Furthermore, the difference between MCT and other types of
therapy was not as large at follow-up as at post-treatment. This
is reflected in the lower bounds of the 95% confidence intervals,
which were close to zero in the follow-up comparison. Thus,
additional randomized controlled trials with larger sample sizes
are needed in order to draw firm conclusions on whether there
are differences in treatment effects between MCT and CBT
interventions. Furthermore, future research should investigate
whether MCT and CBT work differently for different groups of
patients with psychological complaints.
MCT was applied to a large variety of psychological
complaints. The vast majority of trials, however, targeted anxiety
or depression, including post-traumatic stress disorder, as their
primary outcome. Accordingly, our results primarily indicate
that MCT is effective for alleviating anxiety and depression. The
effect ofMCT for other psychological complaints, including grief,
schizophrenia, body dysmorphic disorder, hyposexual desire
disorder, and obsessive compulsive disorder, was only examined
in one trial each. With respect to the comparison with CBT,
the examined studies exclusively targeted anxiety and depression
symptomatology, and therefore they only generalize to this
patient group.
We found that MCT not only produced large effects on
symptoms related to the targeted problem, but also alleviated
secondary, more general symptoms of anxiety and depression.
This indicates that MCT also effectively targets comorbid
problems of anxiety and depression, which is in line with the
theory that MCT targets transdiagnostic processes related to
psychopathology (Wells, 2009). This notion relates directly to
the finding that MCT produced large changes in metacognitive
beliefs and processes at post-treatment and follow-up. In
MCT, metacognitions are conceptualized as transdiagnostic
beliefs and processes that relate to the development and
maintenance of psychological complaints. Visual inspection of
the effects for negative metacognitive beliefs indicates that
they were larger than for positive metacognitive beliefs. This
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finding corresponds with the fact that the primary focus
in therapy is to challenge negative metacognitive beliefs, as
positive metacognitive beliefs about worry and rumination are
also prevalent in the general population and less specific to
psychopathology (Wells, 2009; Sun et al., 2017). Altogether,
these results support the notion that MCT can be effectively
applied as a transdiagnostic approach for patients with different
psychological disorders. Provided that future empirical data
corroborate current results, this would entail great benefits
for clinical practice. Effective transdiagnostic approaches enable
therapists to more easily conceptualize the common maintaining
processes across clinically relevant issues by delivering treatment
strategies within the one protocol. This increases not only the
efficacy but also the efficiency of treatment as well as the ease of
implementation.
Although the pre- to post-treatment effect sizes on the
primary outcome measure were within the large range for all
trials, the effect produced by the individual studies varied,
as indicated by the high degree of heterogeneity. We were
able to explore some of the potential reasons for this. One
explanation for the heterogeneity is found in the type of statistical
analysis used in the studies. As perhaps expected, studies that
used completer analyses produced significantly higher effect
sizes than those that used intent-to-treat analyses. There was
indication that the studies conducted by the originator produced
higher effect sizes. It should be noted, however, that the trials
conducted by other groups also produced a very large effect
size (g = 1.49). More importantly, when the study by Dammen
et al. (2015) was removed, there was no significant difference
between the groups. We found no difference in effect based
on treatment format, when the outlying study was removed,
suggesting that MCT is equally effective in individual and
group formats. Due to the relatively low number of trials, it
was not possible to explore other potential reasons for the
heterogeneity.
This meta-analysis has both strengths and limitations. One
strength compared to the previous meta-analysis on MCT, which
had included three trials on depressive disorders, is that we
were able to include eight trials on depressive disorders. This
enables us to draw stronger conclusions that MCT is an effective
therapy for this group of patients. We were also able to examine
the effect of MCT for a larger range of disorders than anxiety
and depression, which is of relevance, given that meta-analytic
findings suggest that dysfunctional metacognitive beliefs and
processes are found across psychological disorders (Sun et al.,
2017). Furthermore, we were able to more accurately examine
long-term treatment effects of MCT. In the first meta-analysis,
only eight out of 16 studies provided sufficient information
in order to be included in the follow-up analyses, whereas
in this meta-analysis 22 out of 25 studies provided follow-up
data. Another strength relates to the samples of the included
studies. These were samples that were representative of a
clinical population, with high rates of comorbidity and previous
treatment attempts. One limitation to the current meta-analysis
is that we were not able to conduct secondary analyses with use of
controlled effect sizes, due to the low number of studies included.
This poses the risk of over-estimating the effect sizes, as within-
group analyses do not account for changes in symptomatology
over time that are not related to the intervention. Notably,
however, with regard to the primary outcome measure, we did
not find indications that the within-group effect size was over-
estimated, as the pooled effect size for MCT compared to waitlist
was also large. This highlights the relevance of incorporating
open trials, as they continue to provide valuable information
on the efficacy of MCT. A further limitation is that risk of bias
was unclear or high in almost one third of the cases, and it
remains unknown how this may have affected the meta-analytic
results. Lastly, we had limited options in assessing allegiance bias.
Although the subanalyses of studies conducted by the originator
vs. those by other researchers did not show clear indications of
allegiance bias, the author groups may still have favored MCT.
One noticeable exception was the study by Nordahl et al. (2018),
which had a balanced author group with regard to allegiance, as
the originators of both the CBT protocol and MCT protocol took
part in the study.
Based on the results of this systematic review and meta-
analysis, we encourage that future trials on MCT apply
randomized control designs with evidence-based comparison
conditions, particularly when investigating anxiety or depression,
in order to strengthen conclusions on the efficacy of MCT. Based
on our assessment of risk of bias in the studies currently available,
we recommend that future studies improve the quality of
reporting by clarifying how the allocated treatment was concealed
from the participant and investigator up until treatment start, and
that they publish study protocols prior to running the trials, in
order to minimize the risk of bias. Furthermore, results from this
meta-analysis underscore the importance of reporting intent-
to-treat analyses, in order to not overestimate the treatment
effects. Finally, future research needs to examine the efficacy of
MCT applied as a transdiagnostic treatment for different clinical
populations.
In conclusion, the results of this meta-analysis indicate that
MCT is highly effective in reducing symptoms of a range of
primary targeted psychological complaints along with symptoms
of anxiety, depression, and maladaptive metacognitions. There
are preliminary indications that MCTmay be more effective than
other therapeutic interventions, including cognitive behavioral
therapies. However, more studies are needed in order to
investigate the accuracy of these preliminary findings.
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